UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000008874 |
|---|---|
| Receipt number | R000010314 |
| Scientific Title | Feasibility study of photodynamic diagnosis using 5ALA for early head and neck or gastrointestinal cancer |
| Date of disclosure of the study information | 2012/09/07 |
| Last modified on | 2014/11/26 18:52:45 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Feasibility study of photodynamic diagnosis using 5ALA for early head and neck or gastrointestinal cancer
Acronym
Feasibility study of 5ALA-PDD
Scientific Title
Feasibility study of photodynamic diagnosis using 5ALA for early head and neck or gastrointestinal cancer
Scientific Title:Acronym
Feasibility study of 5ALA-PDD
Region
| Japan |
Condition
Condition
early head and neck or gastrointestinal cancer
Classification by specialty
| Gastroenterology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate feasibility of photodynamic diagnosis using 5ALA for early head and neck or gastrointestinal cancer by photodynamic diagnosis for resected these specimens.
Basic objectives2
Others
Basic objectives -Others
Feasibility
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Concordance rate between fluorescence intensity and pathological findings
Key secondary outcomes
Adverse events
Tissue damage by laser.
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Diagnosis
Type of intervention
| Medicine |
Interventions/Control_1
5ALA is administered orally 3 hours before EMR/ESD.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) EMR or ESD is scheduled for following i) or ii) cancer.
i. Tis-T2, N0, M0 oropharynx or hypopharynx cancer
ii. T1, N0, M0 esophagus, stomach ,or colon cancer
2) >= 20 years old.
3) ECOG performance status of <= 1.
4) No prior radiation for cancer in the target organ.
5) Adequate organ function.
6) Written informed consent.
Key exclusion criteria
1) A history of photosensitivity.
2) Porphyria.
3) Women during pregnancy or breast-feeding.
4) Cirrhosis, acute or chronic hepatitis.
5) Systemic treatment is indicated for bacterial or fungal infection.
6) Positive HBs antigen, HCV antibody or known positive serology for HIV.
7) Patient is judged to be inappropriate for study participation for any reason by the investigator.
Target sample size
8
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tomonori Yano |
Organization
National Cancer Center Hospital East
Division name
Gastrointestinal Oncology Division
Zip code
Address
6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan
TEL
04-7133-1111
toyano@east.ncc.go.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Tomoji Kato |
Organization
National Cancer Center Hospital East
Division name
Gastrointestinal Oncology Division
Zip code
Address
6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan
TEL
04-7133-1111
Homepage URL
tomkato@east.ncc.go.jp
Sponsor or person
Institute
National Cancer Center Hospital East
Institute
Department
Personal name
Funding Source
Organization
Health and Labor Sciences Research Grant
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
drug supply : SBI Pharmaceuticals Co., Ltd.
device supply : FUJIFILM Corporation
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
国立がん研究センター東病院（千葉県）
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 09 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 02 | Month | 27 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 09 | Month | 07 | Day |
Last follow-up date
| 2015 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2012 | Year | 09 | Month | 07 | Day |
Last modified on
| 2014 | Year | 11 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010314
